Kymab launches Kymab Access, an academic collaboration programme for the discovery and development of human monoclonal antibodies.
Kymab, a monoclonal antibody biopharmaceutical company, announced today that it has launched Kymab Access, an academic collaboration programme for the discovery and development of human monoclonal antibodies. Leading academic centres of excellence in translational medicine across the world will have the opportunity to evaluate new antibodies discovered on Kymab’s next generation antibody platform.
"Through Kymab Access we are looking forward to collaborating with academic groups that are experts in the biology of human disease and translational medicine,” said Andrew Sandham, Chairman & CEO of Kymab. “Kymab is able to provide next generation human monoclonal antibodies to support these partnerships, in the quest to develop and commercialise innovative medicines."
Through Kymab Access, academic groups can apply to collaborate with Kymab on the discovery and development of human therapeutic antibodies. Based on the academic group’s understanding of disease biology, Kymab will use its Kymouse™ technology to discover lead antibodies for evaluation by academic partners. The Kymouse™ platform comprises a series of transgenic human antibody mouse strains designed to generate high quality, fully human, therapeutic antibodies with minimal requirement for subsequent antibody engineering.
"Our investment in Kymab has allowed technology initiated at the Wellcome Trust Sanger Institute to deliver a world-leading human antibody discovery platform, “ said Sir Mark Walport, Director of the Wellcome Trust. “We are committed to realising broad application of this technology to advance medical research and improve health, including tackling rare diseases and those affecting people in low and middle-income countries, through academic collaboration and industrial innovation."
Kymab Access will operate as an independent affiliate of Kymab to ensure confidentiality of applications from academic groups. A committee of leading academic researchers has been established to oversee the review of applications.